Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Increases By 65.4%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 21,000 shares, an increase of 65.4% from the January 31st total of 12,700 shares. Based on an average trading volume of 74,300 shares, the short-interest ratio is currently 0.3 days.

Global X Genomics & Biotechnology ETF Stock Down 0.9 %

Shares of GNOM stock traded down $0.08 on Tuesday, reaching $8.80. The company had a trading volume of 49,141 shares, compared to its average volume of 68,029. The business’s 50-day moving average is $9.86 and its 200 day moving average is $10.47. Global X Genomics & Biotechnology ETF has a one year low of $8.64 and a one year high of $12.20. The stock has a market capitalization of $61.34 million, a PE ratio of -3.76 and a beta of 1.03.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. bought a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at $50,000. Oxinas Partners Wealth Management LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter worth about $103,000. Sanctuary Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $104,000. Sei Investments Co. bought a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at approximately $114,000. Finally, Smartleaf Asset Management LLC raised its holdings in Global X Genomics & Biotechnology ETF by 11.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock valued at $122,000 after buying an additional 1,265 shares during the last quarter. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.